Dogwood Therapeutics, Inc. · NASDAQ:DWTX
Dogwood Therapeutics — Corporate Update (September 2025)
16 slides from Dogwood Therapeutics's corporate update, Sep 29, 2025
Slide 1: Deepening our Commitment to Patients Suffering from Chemotherapy Induced Peripheral Neuropathy
Deepening our Commitment to Patients Suffering from Chemotherapy Induced Peripheral Neuropathy NASDAQ: DWTX September 29th, 2025
Slide 2: Agenda for Today
NASDAQ: DWTX 2 Agenda for Today ➢Great Progress on Ongoing Halneuron® Phase 2b Chemotherapy Induced Pain Study ➢Exciting New SP16 Cancer Related Pain Global License Overview ➢Q&A
Slide 3: Nav 1.7 Research Pipeline Targeting Chronic and Acute Pain
NASDAQ: DWTX 3 Nav 1.7 Research Pipeline Targeting Chronic and Acute Pain, Includes FDA Fast Track Designation for Treating CINP Target Indication Candidate/Target Preclinical Phase 1 Phase 2 Phase 3 Chemotherapy-Induced Neuropathic Pain (CINP) Halneuron® Nav 1.7 Cancer Related Pain (CRP) Halneuron®
Slide 4: Halneuron 4-Week Phase 2b CINP Study Design
NASDAQ: DWTX 4 80 Patients Have Currently Been Randomized To Treatment In The Halneuron® 4-Week Phase 2b CINP Study Baseline Week 1 Week 2 Week 3 Week 4 Run-in Period Avg. of Days -7 to -1 8 Halneuron® treatment injections spaced over 2 weeks Primary Endpoint End of Study • Primary Objective of the
Slide 5: Key Features of the SP16 IV Transaction
NASDAQ: DWTX 5 Key Features of the SP16 IV Transaction ➢ Royalty free, global license to develop and commercialize Serpin Pharma’s IV formulation of SP16 as a treatment for neuropathy and potentially to repair and/or prevent nerve damage associated with off target effects of chemotherapy ➢ SP16 prov
Slide 6: Exclusive Global License for Serpin Pharma's IV formulation of SP16
NASDAQ: DWTX 6 Exclusive Global License for Serpin Pharma’s IV formulation of SP16 Complements Halneuron® ➢ Serpin benefits from DWTX experience in late-stage development, including pain related conditions ➢ Serpin consideration for the royalty-free, global development and commercialization license
Slide 7: SP16 Target Background
Confidential 7 SP16 Target Background ➢ Alpha 1 antitrypsin (A1AT) is a member of the serpin (serine protease inhibitor family) that plays a critical role in protecting the body from the damaging effects of powerful enzyme proteases, including neutrophil elastase ➢ Neutrophil elastase is released by
Slide 8: SP16 LRP1 Mechanism of Action
Confidential 8 SP16 LRP1 Mechanism of Action
Slide 9: Preclinical Research Demonstrates SP16 Analgesic Effects
NASDAQ: DWTX 9 Preclinical Research Demonstrates SP16 Analgesic Effects Von Frey mechanical hypersensitivity Thermal allodynia
Slide 10: SP16 Inhibits Pain Responses and Inflammation in Peripheral Nerve Injury Model
NASDAQ: DWTX 10 SP16 Inhibits Pain Responses and Inflammation in Peripheral Nerve Injury Model Systemically administered SP16 treatment blocks the development of mechanical hypersensitivity ➢ Tactile allodynia develops after peripheral nerve ligation and are sustained for 14 days ➢ SP16(2μg/g) deliv
Slide 11: SP16 LRP1 Agonism Exhibits Potential to Prevent and/or Repair Nerve Damage
NASDAQ: DWTX 11 SP16 LRP1 Agonism Exhibits Potential to Prevent and/or Repair Nerve Damage Associated Chemotherapy ➢ In collaboration with Dr. Wendy Campana at the University of California San Diego, SP16 was tested for its regenerative effects on neurons ➢ Neurotrophic effects of SP16 and associate
Slide 12: SP16 Does Not Interfere with Common Chemotherapy Regimens In Vitro
NASDAQ: DWTX 12 In-vitro Assays in Several Cancer Types Shows SP16 Does Not Interfere with Common Chemotherapy Regimes In-vitro assays in breast and colon cancer shows SP16 does not interfere with the effectiveness of either platinum or taxane drugs In-vitro assays in pancreatic cancer cells shows S
Slide 13: NCI Funded SP16 Research Plan at University of VA
Confidential 13 NCI Funded SP16 Research Plan to be Finalized with FDA and Executed at University of VA Baseline Chemotherapy SP16 Starting Dose n=6 SP16 Low Dose n=6 SP16 Mid Dose n=6 SP16 High Dose n=6 Placebo n=8 SP16 IV Phase 1b SP16 IV Phase 2a Eligible for NCI Funding Phase 1b Study Endpoints:
Slide 14: Halneuron Fit with SP16 for CINP and Cancer Related Pain
NASDAQ: DWTX 14 Halneuron® Fit with SP16 for CINP and More Broadly for Cancer Related Pain Deal Rationale: ➢ Halneuron® (TTX) = Nav1.7 channel blocker, analgesic → best for treating established CINP pain ➢ Halneuron® is in later-stage development for CINP ➢ SP16 = LRP1-agonist, anti-inflammatory, ne
Slide 15: 2025/2026 CINP/CIPN Research Program Milestones and Catalysts
NASDAQ: DWTX 15 2025/2026 CINP/ CIPN Research Program Milestones and Catalysts Candidate/Target Target Indication Next Key Milestone Halneuron® Nav 1.7 FDA Fast Track Designation for Treatment of CINP Q4 ‘25: New Synthetic Halneuron® IP Filed to Support P3 & Commercialization Q4 ‘25: Recruitment of
Slide 16: Expanding Commitment to Patients Suffering from Neuropathy
NASDAQ: DWTX 16 Expanding Commitment to Patients Suffering from Neuropathy, with Goal to Expand to General Cancer and Post Surgical Pain Target Indication Candidate/Target Preclinical Phase 1 Phase 2 Phase 3 Phase 2b CINP Halneuron® Nav 1.7 General Cancer Pain Halneuron® Nav 1.7 Acute Surgical Pain
Dogwood Therapeutics — Corporate Update (September 2025) on 6ix